Information Provided By:
Fly News Breaks for January 13, 2016
MRTX
Jan 13, 2016 | 06:27 EDT
Citi analyst Yigal Nochomovitz upgraded Mirati Therapeutics to Buy saying the competitive positioning of glesatinib and MGCD516 in non-small cell lung cancer look good. The analyst now estimates MET-alterations occur in 6% of non-small cell lung cancers, up from 2% in his pervious model. He raised his price target for Mirati shares to $48 from $43.
News For MRTX From the Last 2 Days
There are no results for your query MRTX